- Instem lays foundations for next level in drug development services
- Instem’s acquisition of The Edge highly complementary, says broker
- Instem presents ‘Capital Markets Day’
Quick facts: Instem PLC
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum.
Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
19 May 2021
Two acquisitions this year already underline the growing ambition of pharmaceutical services group ().
In a sector where its customers are usually valued in the billions, a desire by Instem to bulk up is understandable.
The business currently is valued at GBP150mln (at 680p) which by AIM standards is meaty enough but in a pharma sector dominated by such as , Merck and , having a bit more clout clearly would be no bad thing.
But there’s more to the recent additions than just adding a bit of muscle.
12 Apr 2021
(LON:INST) saw underlying earnings (EBITDA) rise in 2020 and said it has good visibility for the current year with growing recurring revenues.
The provider of information technology solutions to the life sciences sector said revenue increased 10% to GBP28.2mln in 2020, or by 3% on a like-for-like basis, from GBP25.7mln in 2019.
22 Mar 2021
() acquired US-based clinical trial technology & consulting leader D-Wise Technologies for up to US$31mln in a major step-up of its acquisition plans.
The AIM-listed group has known d-Wise for a decade and said the acquisition should be earnings enhancing in 2021 while also expanding the product offering for large pharma groups.
01 Mar 2021
‘s () acquisition of The Edge, its first deal post fundraising in July, is a highly complementary addition says house broker N+1 Singer.
The company is paying up to GBP8.5mln to acquire The Edge Software Consultancy, which supplies study management and data collection solutions into the drug discovery market.
There are a number of opportunities to drive revenue by leveraging ‘s global infrastructure and sales and marketing capabilities said the broker, which has raised its 2021 and 2022 forecasts by 8% and 15% respectively.
15 Jul 2021
‘s () ‘Capital Markets Day’ is presented by Gary Mitchell, Vice President of Corporate Marketing.
Instem is a leading provider of IT solutions and services to the global early development healthcare market, delivering compelling solutions for data collection, analysis and regulatory submissions management.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…
Instem PLC’s (LON:INS) ‘Capital Markets Day’ is presented by Gary Mitchell, Vice President of Corporate Marketing.
Instem is a leading provider of IT solutions and services to the global early development healthcare market, delivering compelling solutions for data collection, analysis and…
12 hours, 1 minute ago
15 hours, 33 minutes ago
1 day, 13 hours ago
2 days, 13 hours ago
1 week, 2 days ago
2 weeks, 1 day ago
2 weeks, 3 days ago
3 weeks, 2 days ago
1 month ago